Ralliant Corp (RAL) Stock News

A securities class action lawsuit has been filed against GRAIL, Inc. for allegedly providing misleading statements about its NHS-Galleri trial results. The company allegedly concealed material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is August 4, 2026.

Hagens Berman is investigating GRAIL, Inc. for allegedly misleading investors about its NHS-Galleri cancer screening trial. The company failed to disclose that a three-year follow-up period was insufficient to meet the trial's primary endpoint. When GRAIL revealed the trial failure on February 19, 2026, its stock collapsed 50.55%, erasing $2.2 billion in market capitalization. The class action covers the period from May 13, 2025 to February 19, 2026, with a lead plaintiff deadline of August 4, 2026.

Hagens Berman is investigating GRAIL, Inc. for allegedly misleading investors about its NHS-Galleri cancer screening trial. The company failed to disclose that a three-year follow-up period was insufficient to meet the trial's primary endpoint. When GRAIL revealed the trial failure on February 19, 2026, its stock collapsed 50.55%, erasing $2.2 billion in market capitalization. The class action period spans May 13, 2025 to February 19, 2026, with a lead plaintiff deadline of August 4, 2026.

Law firm Robbins Geller Rudman & Dowd LLP announced class action lawsuits against GRAIL, Inc. (NASDAQ: GRAL) for allegedly making false statements about its NHS-Galleri cancer screening trial. GRAIL failed to achieve the primary endpoint of reducing Stage III-IV cancers, causing the stock to fall over 50% on February 19, 2026. The firm is seeking lead plaintiffs from investors who purchased GRAL stock between May 13, 2025 and February 19, 2026. Similar lawsuits were also filed against Commvault Systems, Inc. and PicS N.V.

Grail, Inc. (NASDAQ: GRAL) faces a class action securities fraud lawsuit after failing to meet the primary endpoint in its NHS-Galleri cancer trial on February 19, 2026. The announcement caused the stock to plummet 50.5%. Investors allege the company made materially false statements about trial results and failed to disclose that the three-year timeline was insufficient to demonstrate the primary endpoint, misleading shareholders about business prospects.

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The company allegedly concealed that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The lead plaintiff deadline is August 4, 2026.

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Berger Montague has filed a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL failed to disclose that the NHS-Galleri trial was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. On February 19, 2026, GRAIL announced the trial's primary endpoint had not been met, causing the stock to plummet approximately 50.55% in a single trading day from $101.53 to $50.21 per share. The lead plaintiff deadline is August 4, 2026.

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The complaint claims defendants provided overly positive statements while concealing material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be entitled to compensation. The lead plaintiff deadline is August 4, 2026.

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. A securities class action lawsuit alleges the company misled investors about the trial's design and likelihood of success, claiming management knew a three-year follow-up period would be insufficient but expressed high confidence anyway. The stock plunged over 50% following the announcement.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Badger Meter, Grail, Inc., and PicS N.V. The lawsuits allege materially false statements and/or failure to disclose material facts. Badger Meter faces allegations regarding order pull-forward practices, Grail regarding its NHS-Galleri trial, and PicS regarding credit evaluation procedures in its IPO. Investors who suffered losses during the relevant periods are encouraged to seek lead plaintiff status.

GRAIL, Inc. faced a securities class action lawsuit after its NHS-Galleri trial failed to meet its primary endpoint on February 20, 2026, resulting in a $2.2 billion market capitalization loss and over 50% stock price decline. The lawsuit alleges GRAIL misled investors about the trial's design and likelihood of success, with the company later admitting it should have allowed for a longer follow-up period than the three years originally touted.

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 of an important August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided overwhelmingly positive statements while concealing material adverse facts about its NHS-Galleri trial, specifically that the trial period was insufficient to demonstrate the achievability of reducing Stage III-IV cancers and that the company refused to provide detailed results.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Grail, Inc. (NASDAQ: GRAL) for allegedly making false and misleading statements about its NHS-Galleri cancer detection trial. The company touted confidence in the trial's success while concealing that the three-year trial period was insufficient to achieve its primary endpoint. On February 19, 2026, Grail announced the primary endpoint was not met, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Rosen Law Firm is reminding investors in GRAIL, Inc. (NASDAQ: GRAL) who purchased stock between May 13, 2025 and February 19, 2026 of an August 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that GRAIL provided misleading statements about its NHS-Galleri trial results, concealing material adverse facts about the trial's ability to demonstrate cancer reduction outcomes. Investors may be eligible for compensation through a contingency fee arrangement.

Robbins LLP has filed a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025 and February 19, 2026. The lawsuit alleges that Grail misled investors about the success probability of its NHS-Galleri trial, which failed to achieve its primary endpoint. Following the announcement on February 19, 2026, Grail's stock price plummeted approximately 50.55% in a single trading day, from $101.53 to $50.21 per share.

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. A securities class action lawsuit alleges the company misled investors about the trial's design and likelihood of success, claiming GRAIL had internal information suggesting three years would be insufficient for the trial but expressed high confidence anyway. The stock plunged over 50% following the announcement.

The Schall Law Firm is seeking investors who purchased GRAIL, Inc. securities between May 13, 2025 and February 19, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its NHS-Galleri trial's prospects in reducing Stage III-IV cancers, overstating optimism while concealing adverse trial data.

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 of an important August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided overwhelmingly positive statements while concealing material adverse facts about its NHS-Galleri trial, specifically that the trial period was insufficient to demonstrate the achievability of reducing Stage III-IV cancers and that defendants withheld detailed results.

Grail, Inc. (GRAL) shares collapsed 50.55% on February 20, 2026, after the company disclosed that the NHS-Galleri trial failed to meet its primary endpoint for statistically significant Stage III-IV cancer reduction. A securities class action has been filed alleging that management made misleading positive representations about the trial to analysts and investors throughout the class period (May 13, 2025 - February 19, 2026), resulting in artificially inflated stock prices. The lead plaintiff deadline is August 4, 2026.

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 of an August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided overwhelmingly positive statements while concealing material adverse facts about its NHS-Galleri trial, specifically that the trial period was insufficient to demonstrate the achievability of reducing Stage III-IV cancers and that detailed results were withheld from investors.

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. The company faces a securities class action lawsuit alleging it misled investors about the trial's design and likelihood of success, claiming it had information suggesting three years would be insufficient for the trial but expressed high confidence anyway. The stock plunged over 50% following the announcement.

The Gross Law Firm has issued a securities class action deadline alert for GRAIL, Inc. investors. The lawsuit alleges that GRAIL made materially false and misleading statements about its NHS-Galleri trial while concealing adverse facts. On February 19, 2026, GRAIL announced the trial failed to meet its primary endpoint of demonstrating a statistically significant reduction in Stage III-IV cancers, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. The deadline for lead plaintiff appointment is August 4, 2026.

Moore Law PLLC is investigating potential securities fraud claims against Grail, Inc., alleging the company made false and misleading statements that artificially inflated its stock price. Grail's shares plummeted approximately 50.55% in a single trading day on February 20, 2026, falling from $101.53 to $50.21 per share. The law firm is encouraging affected shareholders to contact them for potential monetary damages and corporate governance reforms.

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. The company faces a securities class action lawsuit alleging it misled investors about the trial's design and likelihood of success, claiming it had information suggesting three years would be insufficient for the trial but expressed high confidence anyway. The stock plunged over 50% following the announcement.

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 of an important August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided overwhelmingly positive statements while concealing material adverse facts about its NHS-Galleri trial, including that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers.

The Schall Law Firm is seeking investors who purchased GRAIL, Inc. securities between May 13, 2025 and February 19, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its NHS-Galleri trial's prospects in reducing Stage III-IV cancers, overstating optimism while concealing adverse trial data.

Grabar Law Office has filed multiple shareholder investigations and securities fraud class actions against Badger Meter, GeneDx Holdings, GRAIL Inc., and Verra Mobility Corporation, alleging that company officers and directors made false or misleading statements about financial performance, business acquisitions, clinical trial results, and contract renewals. All four companies experienced significant stock price declines following disclosure of the alleged misconduct.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Grail, Inc. (NASDAQ: GRAL) for allegedly making false and misleading statements about its NHS-Galleri cancer detection trial. The company touted confidence in the trial's success while concealing that the trial period was insufficient to achieve its primary endpoint. On February 19, 2026, Grail announced the primary endpoint was not observed, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 have until August 4, 2026 to seek lead plaintiff status.

The Schall Law Firm is seeking investors who purchased GRAIL, Inc. securities between May 13, 2025 and February 19, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its NHS-Galleri trial's prospects in reducing Stage III-IV cancers, concealing adverse data while presenting overly optimistic projections about the three-year study timeline.